The DOI matches its Crossref record.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)
Abstract
How does once-weekly subcutaneous tirzepatide affect maintenance of weight loss in individuals with obesity or overweight? Methods : SURMOUNT-4 is a phase 3, double-blind, 88-week study that investigates the maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg QW), compared with placebo, on the maintenance of weight loss for 52 weeks after an initial 36-week open-label tirzepatide lead-in treatment period. In the study, participants without T2DM and with obesity (BMI ≥30 kg/m^2) or overweight (BMI ≥27 kg/m^2) with at least 1 weight-related comorbid condition were enrolled. The efficacy estimand was used to assess efficacy which represented the average treatment effect, prior to treatment discontinuation. Results : 803 participants enrolled in the lead-in period and 670 were randomized to continue tirzepatide MTD (N=335) or switch to placebo (N=335). For randomized participants, the mean weight loss was 20.9% following 36-week open-label treatment. SURMOUNT-4 met the primary endpoint. From week 36 to week 88, those taking tirzepatide had an additional weight change of -6.7%, while those taking placebo had a mean weight regain of 14.8%. The percentage of participants at 88 weeks who maintained ≥80% of the weight loss during the lead-in period was 93.4% with tirzepatide and 13.5% with placebo. In addition, participants who remained on tirzepatide achieved a total of 26.0% mean weight loss over the 88-week period. The most frequent adverse events with tirzepatide were gast…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the end of the SURMOUNT-4 study (88 weeks from baseline), 25.9% of people at the placebo group were able to achieve ≥ 15% WL compared to 84.1% at the tirzepatide group.”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [49]
In the citing paper
“At the end of the 36-week tirzepatide lead-in period, participants achieved 21.1% mean WL. Those taking tirzepatide, managed an additional 5.5% WL from randomisation, compared to those taking placebo who experienced mean weight regain of 14% from randomisation [49].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [49]
In the citing paper
“Most pivotal trials, including the STEP 1 extension and the SURMOUNT-4 trial, terminate approximately 52 weeks after treatment withdrawal (Wilding et al., 2022; Aronne et al., 2024).”
From IS OBESITY PHARMACOTHERAPY A LIFETIME COMMITMENT? A STRUCTURED REVIEW OF WEIGHT REGAIN AND STRATEGIES FOLLOWING INCRETIN CESSATION (2026) · cites this paper as Aronne et al., 2024
In the citing paper
“Waist circumference: −4.3 cm (tirzepatide) vs. +7.8 cm (placebo)”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [31]
In the citing paper
“This resulted in a total weight loss of 25.3% from baseline.”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [31]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Richards, R., Lunt, W., Whitman, M., Spaltro, G., & Hall, R. (2025) · JMIR Formative Research · doi:10.2196/81912 · Cited by 15
Metadata
- Authors
- Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & Ebert, T.
- Affiliations
- Weill Cornell Medicine (US)
- University of Glasgow (GB)
- University of Texas McGovern Medical School, University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, Houston, Texas , United States
- Louisville Metabolic and Atherosclerosis Research Center (US)
- McMaster University (CA)
- China Medical University Hospital (TW)
- Eli Lilly (United States) (US)
- University Hospital Leipzig (DE)
- ORCID
- Venue
- Diabetologie und Stoffwechsel
- Publisher
- Georg Thieme Verlag KG
- Published
- 2024-04
- Volume
- 19
- Issue
- S 01
- Pages
- S84-S85
- ISSN
- 1861-9002 (ISSN-L)
- 1861-9010
- OpenAlex
- W4394936275
- Cited by
- 13
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 5
- FWCI
- 3.71
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Diabetologie und Stoffwechsel (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, obesity, overweight, weight loss maintenance, weight regain, maximum tolerated dose, weight-related comorbidities, gastrointestinal adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). https://app.cochat.ai/papers/10.1055/s-0044-1785403
- The paper
- Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & Ebert, T. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). Diabetologie und Stoffwechsel. https://doi.org/10.1055/s-0044-1785403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.